Delays to cancer testing and treatment will be “inevitable” as a result of a no-deal Brexit.
News
Scotland’s children at risk due to lack of doctors
Scotland’s lack of paediatric doctors is putting young people at risk, according to a new report by the Royal College of Paediatrics and Child Health (RCPCH).
Promising Innovative Medicine granted to Bulevirtide for Hep D
MYR Pharma’s Bulevirtide has been awarded a Promising Innovative Medicine as a treatment for hepatitis D infections, indicating that the drug is a strong contender for the UK’s Early Access to Medicinces Scheme (EAMS).
Novo Nordisk seeks label update for Fiasp in children
Novo Nordisk has submitted applications to both US and EU regulators for use of its fast-acting insulin Fiasp in children.
PharmaTimes is proud to announce the launch of the 2019 Sales Awards!
This year’s event builds on the phenomenal success of the 2018 re-launch of this highly respected competition – recognising and rewarding the most talented sales professionals working within the healthcare industry.
Iksuda signs licence agreement with Femtogenix for solid tumours
Iksuda Therapeutics and Femtogenix have signed a licensing agreement for antibody-drug conjugates.
Merck KGaA, Pfizer added to BioXcel’s pancreatic cancer deal
Merck KGaA and Pfizer have joined BioXcel and Nektar Therapeutics’ clinical collaboration to test Bavencio in combination with two other cancer therapies as a treatment for pancreatic cancer.
PHE launches ‘Cervical Screening Saves Lives’ campaign
A new cervical cancer screening campaign has been launched by Public Health England, as screenings fall to a 20-year low.
Major study again rejects that vaccinations cause autism
A new study has found “no increased risk for autism after MMR vaccination”.
BBC warns of illegal STI drugs being sold online
A BBC reporter has discovered an online trade of illegal drugs for STIs.
Verona announces positive results from Phase II COPD trial
Verona Pharma’s COPD inhaler has shown positive results in a Phase II study.
Study shows long-term efficacy for Ilumya in psoriasis
Sun Pharma’s Ilumya has proven to be efficient for up to three years of ongoing treatment.
Lynparza, Dupixent backed by CHMP for label extensions
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended extending the uses of AstraZeneca’s Lynparza and Sanofi’s Dupixent.
Syncona’s Nightstar Therapeutics to be bought by Biogen for $877 million
Nightstar Therapeutics has agreed to be acquired by Biogen.
EMA accepts marketing authorisation applications for Idefirix and Xospata
European regulators have accepted for review marketing authorisation applications for Hansa’s Idefirix and Astellas’ Xospata.
